Cargando…

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

BACKGROUND: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. METHODS: The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boers, Maarten, Hartman, Linda, Opris-Belinski, Daniela, Bos, Reinhard, Kok, Marc R, Da Silva, Jose AP, Griep, Eduard N, Klaasen, Ruth, Allaart, Cornelia F, Baudoin, Paul, Raterman, Hennie G, Szekanecz, Zoltan, Buttgereit, Frank, Masaryk, Pavol, Klausch, L Thomas, Paolino, Sabrina, Schilder, Annemarie M, Lems, Willem F, Cutolo, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209692/ https://www.ncbi.nlm.nih.gov/pubmed/35641125 http://dx.doi.org/10.1136/annrheumdis-2021-221957

Ejemplares similares

Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial
por: Güler-Yüksel, Melek, et al.
Publicado: (2023)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial
por: Akdemir, G, et al.
Publicado: (2016)

Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
por: Błyszczuk, Przemysław, et al.
Publicado: (2020)

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Age affects joint space narrowing in patients with early active rheumatoid arthritis
por: Matthijssen, X M E, et al.
Publicado: (2016)

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
por: van der Pol, Joy Ardjuna, et al.
Publicado: (2023)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
por: van Boheemen, Laurette, et al.
Publicado: (2021)

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis
por: Perpétuo, Inês Pedro, et al.
Publicado: (2017)

Don’t neglect nutrition in rheumatoid arthritis!
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Complex role of oestrogens in the risk and severity of rheumatoid arthritis in menopause
por: Cutolo, Maurizio, et al.
Publicado: (2023)

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis
por: Pál, Ildikó, et al.
Publicado: (2017)

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2015)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, Sophie, et al.
Publicado: (2019)

Prospective, simultaneous assessment of joint and vascular inflammation by PET/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status
por: Hamar, Attila, et al.
Publicado: (2021)

Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count
por: Hartman, Linda, et al.
Publicado: (2021)

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition
por: Dietzel, Roswitha, et al.
Publicado: (2022)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial
por: Seppen, Bart, et al.
Publicado: (2022)

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples
por: Kissel, Theresa, et al.
Publicado: (2022)

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids
por: Hartman, Linda, et al.
Publicado: (2022)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
por: Farragher, Tracey M, et al.
Publicado: (2008)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Symptom Complexes at the Earliest Phases of Rheumatoid Arthritis: A Synthesis of the Qualitative Literature
por: Stack, Rebecca J, et al.
Publicado: (2013)

Brief Report: Deficient Thymic Output in Rheumatoid Arthritis Despite Abundance of Prethymic Progenitors
por: Wagner, Ulf, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8p3t7s6qn2jh4a2ij88oaumkqe